Abeona Therapeutics Inc. (NASDAQ:ABEO) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) have received a consensus rating of “Moderate Buy” from the five analysts that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $20.00.

A number of equities analysts have commented on the stock. Weiss Ratings downgraded shares of Abeona Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, October 24th. Oppenheimer boosted their price target on shares of Abeona Therapeutics from $19.00 to $20.00 and gave the stock an “outperform” rating in a research note on Friday, August 15th. Wall Street Zen cut shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Abeona Therapeutics in a report on Monday, October 13th.

Abeona Therapeutics Stock Up 3.0%

ABEO opened at $4.87 on Friday. Abeona Therapeutics has a 52 week low of $3.93 and a 52 week high of $7.54. The business has a 50 day moving average price of $4.99 and a two-hundred day moving average price of $5.86. The company has a quick ratio of 9.53, a current ratio of 9.74 and a debt-to-equity ratio of 0.06. The company has a market cap of $263.91 million, a PE ratio of 3.96 and a beta of 1.12.

Abeona Therapeutics (NASDAQ:ABEO) last released its earnings results on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.17. As a group, research analysts anticipate that Abeona Therapeutics will post -1.16 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Vishwas Seshadri sold 25,000 shares of Abeona Therapeutics stock in a transaction that occurred on Tuesday, September 30th. The stock was sold at an average price of $5.24, for a total value of $131,000.00. Following the sale, the chief executive officer directly owned 1,190,067 shares in the company, valued at $6,235,951.08. The trade was a 2.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Joseph Walter Vazzano sold 9,035 shares of the stock in a transaction on Monday, September 29th. The stock was sold at an average price of $5.39, for a total value of $48,698.65. Following the completion of the transaction, the chief financial officer owned 453,631 shares of the company’s stock, valued at $2,445,071.09. The trade was a 1.95% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 78,612 shares of company stock valued at $410,271 over the last 90 days. 6.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ABEO. Ameritas Investment Partners Inc. acquired a new stake in shares of Abeona Therapeutics during the 2nd quarter valued at approximately $25,000. Legal & General Group Plc acquired a new stake in shares of Abeona Therapeutics in the 2nd quarter worth approximately $27,000. Russell Investments Group Ltd. purchased a new position in Abeona Therapeutics in the 3rd quarter valued at approximately $37,000. Legato Capital Management LLC acquired a new position in Abeona Therapeutics during the third quarter worth $57,000. Finally, Riverwater Partners LLC purchased a new stake in Abeona Therapeutics during the second quarter worth $62,000. 80.56% of the stock is currently owned by institutional investors and hedge funds.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.